NantHealth saw its stock price close down 23 percent on Monday, on the heels of a report from STAT showing how Dr. Patrick Soon-Shiong used philanthropy to boost his health technology company.
As investors soured on the stock, a health care analyst defended the company and a law firm put out a call for participants in a potential class action investor suit.
Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!
GET STARTEDWhat is it?
STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.
What's included?
- Daily reporting and analysis
- The most comprehensive industry coverage from a powerhouse team of reporters
- Subscriber-only newsletters
- Daily newsletters to brief you on the most important industry news of the day
- Online intelligence briefings
- Frequent opportunities to engage with veteran beat reporters and industry experts
- Exclusive industry events
- Premium access to subscriber-only networking events around the country
- The best reporters in the industry
- The most trusted and well-connected newsroom in the health care industry
- And much more
- Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
About the Author
Wouldn’t surprise me to see NantHealth’s lawyers to come after STATnews (even if just a sort of SLAPP reprisal action). Hope the article was fully legally vetted prior to publication.